ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as "leukemic phase"

Leukemia Research

Volumn 34, Issue 4, 2010, Pages 475-482

  Lu, Ying ^a,b   Zhao, Xiaohui ^a,c   Wang, Endi ^d   Chen, Wei ^a,e   Huang, Qin ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b NINGBO FIRST HOSPITAL   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e The Affiliated Sir Run Run Hospital of Nanjing Medical University   (China)

Author keywords

Anaplastic large cell lymphoma; Bone marrow and blood; Leukemic phase

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE;

ADULT; AGE; ARTICLE; BONE MARROW BIOPSY; BONE MARROW METASTASIS; CANCER INVASION; CANCER MORPHOLOGY; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOMA CELL; MALE; MEDICAL RECORD REVIEW; MENINGEAL METASTASIS; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROGNOSIS;

ADULT; BONE MARROW NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROTEIN-TYROSINE KINASES;

EID: 76749113327     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.07.034     Document Type: Article

References (37)

1. Stein H., Mason D.Y., Gerdes J., O'Connor N., Wainscoat J., Pallesen G., et al. The expression of the Hodgkin's disease-associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66 (1985) 848-858
2. Rimokh R., Magaud J.P., Berger F., Samarut J., Coiffier B., Germain D., et al. A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ("Ki-1lymphoma"). Br J Haematol 71 (1989) 31-36
3. Kaneko Y., Frizzera G., Edamura S., Maseki N., Sakurai M., Komada Y., et al. A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis. Blood 73 (1989) 806-813
4. Mason D.Y., Harris N.L., and Delsol G. Anaplastic large cell lymphoma, ALK-negative. In: Swerdlow S., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al. (Eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (2008), IARC Press, Lyon 317-319
5. Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G., Shapiro D.N., Saltman D.L., et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263 (1994) 1281-1284
6. Pulford K., Lamant L., Morris S.W., Butler L.H., Wood K.M., Stroud D., et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89 (1997) 1394-1404
7. Jaffe E.S. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol 14 (2001) 219-228
8. Downing J.R., Shurtleff S.A., Zielenska M., Curcio-Brint A.M., Behm F.G., Head D.R., et al. Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction. Blood 85 (1995) 3416-3422
9. Shiota M., Nakamura S., Ichinohasama R., Abe M., Akagi T., Takeshita M., et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 86 (1995) 1954-1960
10. Lamant L., Meggetto F., Al Saati T., Brugières L., de Paillerets B.B., Dastugue N., et al. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease: comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood 87 (1996) 284-291
11. Greer J.P., Kinney M.C., Collins R.D., Salhany K.E., Wolff S.N., Hainsworth J.D., et al. Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma. J Clin Oncol 9 (1991) 539-547
12. + T-cell lymphoma. Am J Surg Pathol 17 (1993) 859-868
13. Anderson M.M., Ross C.W., Singleton T.P., Sheldon S., and Schnitzer B. Ki-1 anaplastic large cell lymphoma with a prominent leukemic phase. Hum Pathol 27 (1996) 1093-1095
14. Bayle C., Charpentier A., Duchayne E., Manel A.M., Pages M.P., Robert A., et al. Leukemia presentation of small cell variant anaplastic large cell lymphoma: report of four cases. Br J Haematol 104 (1999) 680-688
15. Villamor N., Rozman M., Esteve J., Aymerich M., Colomer D., Aguilar J.L., et al. Anaplastic large-cell lymphoma with rapid evolution to leukemic phase. Ann Hematol 78 (1999) 478-482
16. Tilly H., Gaulard P., Lepage E., Dumontet C., Diebold J., Plantier I., et al. Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood 90 (1997) 3727-3734
17. Wong K.F., Chan J.K., Ng C.S., Chu Y.C., Lam P.W., Yuen H.L., et al. Anaplastic large cell Ki-1 lymphoma involving bone marrow: marrow findings and association with reactive hemophagocytosis. Am J Hematol 37 (1991) 112-119
18. Tamura K., Tashiro H., Kondoh S., Kisanuki A., Sumiyoshi A., Suzumiga J., et al. Ki-1 (CD30)-positive large cell lymphoma present with leukemia: a case report. Fukuoka Igaku Zasshi 85 (1994) 366-371
19. Awaya N., Mori S., Takeuchi H., Mori S., Sugano Y., Kamata T., et al. CD30 and the NPM-ALK fusion protein (p80) are differentially expressed between peripheral blood and bone marrow in primary small cell variant of anaplastic large cell lymphoma. Am J Hematol 69 (2002) 200-204
20. Falini B., Pileri S., Zinzani P.L., Carbone A., Zagonel V., Wolf-Peeters C., et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 93 (1999) 2697-2706
21. Clavio M., Rossi E., Truini M., Carrara P., Ravetti J.L., Spriano M., et al. Anaplastioc large cell lymphoma: a clinicopathologic study of 53 patients. Leuk Lymphoma 22 (1996) 319-327
22. Fraga M., Brousset P., Schlaifer D., Payen C., Robert A., Rubie H., et al. Bone marrow involvement in anaplastic large cell lymphoma. Immunohistochemical detection of minimal disease and its prognostic significance. AM J Clin Pathol 103 (1995) 82-89
23. Benharroch D., Meguerian-Bedoyan Z., Lamant L., Amin C., Brugières L., Terrier-Lacombe M.J., et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 91 (1998) 2076-2084
24. Delsol G., Saati T., Gatter K., Gerdes J., Schwarting R., Caveriviere P., et al. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas: diagnostic value in so-called malignant histiocytosis. Am J Pathol 130 (1988) 59-70
25. Foss H.D., Anagnostopoulos I., Araujo I., Assaf C., Demel G., Kummer J.A., et al. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood 88 (1996) 4005-4011
26. Wellmann A., Otsuki T., Vogelbruch M., Clark H.M., Jaffe E.S., Raffeld M., et al. Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's of T-cell phenotype, and in Hodgkin's disease. Blood 86 (1995) 2321-2328
27. Savage K.J., Harris N.L., Vose J.M., Ullrich F., Jaffe E.S., Connors J.M., et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111 (2008) 5496-5504
28. Onciu M., Behm F.G., Raimondi S.C., Moore S., Harwood E.L., Pui C.H., et al. ALK-positive anaplastic large cell lymphoma with leukemic peripheral blood involvement is a clinicopathologic entity with an unfavorable prognosis: report of three cases and review of the literature. Am J Clin Pathol 120 (2003) 617-625
29. Monaco S., Tsao L., Murty V.V., Nandula S.V., Donovan V., et al. Pediatric ALK+ anaplastic large cell lymphoma with t(3;8)(q26.2;q24) translocation and c-myc rearrangement terminating in a leukemic phase. Am J Hematol 82 (2007) 59-64
30. Takahashi D., Nagatoshi Y., Nagayama J., Inagaki J., Itonoaga N., Takeshita M., et al. Anaplastic large cell lymphoma in leukemic presentation: a case report and a review of the literature. J Pediatr Hematol Oncol 30 9 (2008) 696-700
31. Grewal J.S., Smith L.B., Winegarden III J.D., Krauss J.C., Tworek J.A., and Schnitzer B. Highly aggressive ALK-positive anaplastic large cell lymphoma with a leukemic phase and multi-organ involvement: a report of three cases and a review of the literature. Ann Hematol 86 (2007) 499-508
32. Matsushita H., Nakamura N., Asai S., Yabe M., Hayama N., and Kondo Y. A leukemic change as an initial manifestation of the common variant type of ALK-positive anaplastic large cell lymphoma in a patient with lung adenocarcinoma. Intern Med 47 (2008) 2057-2062
33. Lamant L., de Reynies A., Duplantier M.M., Rickman D.S., Sabourdy F., Giuriato S., et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals difference based on ALK status and two distinct morphologic ALK+ subtypes. Blood 109 (2007) 2156-2164
34. Kong S.Y., Cho H.J., Suk J.H., Tak E.Y., Ko Y.H., Kim K., et al. A novel complex t(2;5;13)(p23;q35;q14) in small cell variant type anaplastic large cell lymphoma with peripheral involvement. Cancer Genet Cytogenet 154 (2004) 183-185
35. Meech S.J., McGavran L., Odom L.F., Liang X., Meltesen L., Gump J., et al. Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4-anaplastic lymphoma kinase gene fusion. Blood 98 (2001) 1209-1216
36. Dalal B.I., Chhanabhai M., Horsman D.E., LeHuquet J., and Coupland R. Anaplastic large-cell lymphoma presenting as acute leukemia. Am J Hematol 79 (2005) 164-165
37. Nguyen J.T., Condron M.R., Nguyen N.D., De J., Medeiros L.J., and Padula. Anaplastic large cell lymphoma in leukemic phase: extraordinarily high white blood cell count. Pathol Int 59 May (5) (2009) 345-353